← Back to Search

Vitamin D Analog

Calcipotriol for Central Centrifugal Alopecia (CCCA Trial)

Phase < 1

Waitlist Available

Led By Amy McMichael, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 2, month 4, and month 6

Awards & highlights

All Individual Drugs Already Approved

Summary

This trial is testing calcipotriol, a vitamin D-like cream, on patients with CCCA. These patients often have low vitamin D levels. The cream may help by reducing inflammation and supporting immune health around hair follicles. Calcipotriol has been studied for its effectiveness in treating conditions like psoriasis and alopecia areata.

Eligible Conditions

Central Centrifugal Cicatricial Alopecia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 2, month 4, and month 6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 2, month 4, and month 6

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 2, month 4, and month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Amount of hairline stabilization

Secondary study objectives

Amount of hair regrowth

Dermatology Life Quality Index score

Signs and symptoms of disease score

Side effects data

From 2010 Phase 3 trial • 1245 Patients • NCT00691002

Psoriasis

Headache

Pruritus

Erythema

Nasopharyngitis

Pyrexia

Herpes simplex

Skin irritation

Rhinitis

Diarrhoea

Toothache

Application site pruritus

Influenza

Burning sensation

100%

80%

60%

40%

20%

Study treatment Arm

LEO 80190

Calcipotriol

Hydrocortisone

LEO 80190 Vehicle

Open-label Phase

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Calcipotriol GroupExperimental Treatment1 Intervention

Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.

Group II: Control GroupPlacebo Group1 Intervention

Subjects will continue to use their primary physician prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Calcipotriol

FDA approved

Do I qualify?Apply below to find out